Lung Cancer

First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or metastatic NSCLC.

Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for patients with solid tumors.

The FDA has granted priority review to an NDA for taletrectinib in the treatment of advanced ROS1-positive non–small cell lung cancer.

From tennis star Gabriela Dabrowski sharing details of her breast cancer journey to Greg Gumbel and Linda Lavin dying, here is the latest cancer news.

CURE compiled the top stories in the lung cancer space, including treatment updates and the potential of cancer vaccines.

The FDA approved several drugs in December for the treatment of diseases, including pancreatic adenocarcinoma, lung cancer, skin cancer and graft-versus-host disease.

Opdivo Qvantig received FDA approval for all previously approved indications in solid tumors.

The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who progressed on/after chemotherapy.

As we near the end of 2024, CURE is looking back at the top FDA approval stories of the year.

A survivor shares tips on ways to practice gratitude the holiday season.

The Food and Drug Administration has approved Ensacove for patients with ALK-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK-inhibitor.

At CURE, we remain steadfastly dedicated to providing our readers with answers about cancer research.

Imfinzi was approved by the FDA for the treatment of adults with limited-stage small cell lung cancer without disease progression after chemotherapy and radiation.

The FDA has approved the first systemic therapy for patients with NSCLC or pancreatic adenocarcinoma with an NRG1 gene fusion.

The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic nonsquamous NSCLC with EGFR mutations.

In patients with advanced solid tumors, treatment with nemvaleukin with or without Keytruda demonstrated antitumor activity and tolerability.

The primary endpoint of overall survival was missed in the SKYSCRAPER-01 study assessing tiragolumab plus Tecentriq in some patients with non-small cell lung cancer.

The FDA approved several drugs throughout November for the treatment of diseases including leukemia and biliary tract cancer, in addition to a diagnostic for solid cancers.

Through cancer and life’s challenges, having and showing gratitude changed everything for me.

For patients with extensive-stage small cell lung cancer, Loqtorzi was shown to improve progression-free survival and overall survival.

Celebrating Thanksgivings after cancer has made me appreciate all aspects of life even more and to truly cherish times of laughter and memories.

Patients with metastatic non-small cell lung cancer and high CD47 expression showed improved responses to treatment with magrolimab plus docetaxel.

Treatment with subcutaneous Keytruda plus berahyaluronidase alfa meets phase 3 trial end points in the treatment of metastatic non–small cell lung cancer.

CURE® spoke with a lung cancer treatment expert about study findings showing survival benefits with the addition of radiotherapy to TKI treatment.

A patient with small cell lung cancer shared her clinical trial experience with CURE® and how she encourages other patients with cancer to enroll.

RNA from the COVID-19 infection in patients with certain metastatic cancers may be associated with tumor shrinkage, but more research is necessary.

For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated approval of Dato-DXd.

The anti-TIGIT therapy, vibostolimab, plus Keytruda and chemotherapy did not improve overall survival versus Tecentriq plus chemotherapy in extensive-stage small cell lung cancer.

In patients with advanced NSCLC, treatment with Jemperli plus chemotherapy showed promising effectiveness compared with Keytruda plus chemotherapy.

The combination of THIO and Libtayo has shown promising results among patients with advanced checkpoint inhibitor-resistant non-small cell lung cancer.